Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA approved on December 27, 2005.

Structure

Similar Structures

Synonyms

1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Lenalidomida
Lenalidomide

External IDs

CC-5013 / CDC 501 / CDC-501 / ENMD 0997 / SYP-1512

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Revlimid	Capsule	2.5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable
Revlimid	Capsule	5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable
Revlimid	Capsule	20 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable
Revlimid	Capsule	25 mg	Oral	Celgene	2008-10-10	Not applicable
Revlimid	Capsule	5 mg/1	Oral	Celgene Corporation	2005-12-27	Not applicable
Revlimid	Capsule	25 mg/1	Oral	Celgene Corporation	2006-06-29	Not applicable
Revlimid	Capsule	25 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable
Revlimid	Capsule	5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable
Revlimid	Capsule	15 mg	Oral	Celgene	2008-10-10	Not applicable
Revlimid	Capsule	2.5 mg/1	Oral	Celgene Corporation	2012-04-16	Not applicable

Additional Data Available

Application Number

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

International/Other Brands

Ladevina / Lenangio

Categories

UNII

F0P408N6V4

CAS number

191732-72-6

Weight

Average: 259.2606
Monoisotopic: 259.095691297

Chemical Formula

C₁₃H₁₃N₃O₃

InChI Key

GOTYRUGSSMKFNF-UHFFFAOYSA-N

InChI

InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

IUPAC Name

3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

SMILES

NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O

Pharmacology

Indication

Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Associated Conditions

Pharmacodynamics

Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.

Mechanism of action

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity

Target	Actions	Organism
AProtein cereblon	inhibitor	Humans
ATumor necrosis factor ligand superfamily member 11	inhibitor	Humans
UCadherin-5	antagonist	Humans
UProstaglandin G/H synthase 2	negative modulator	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (C_max) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.

Volume of distribution

Not Available

Protein binding

30% protein bound.

Metabolism

Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.

Route of elimination

Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.

Half life

Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.

Clearance

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

Toxicity

The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
Unlock Additional Data
(R)-warfarin	The risk or severity of bleeding can be increased when (R)-warfarin is combined with Lenalidomide.
(S)-Warfarin	The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Lenalidomide.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Lenalidomide is combined with 2-Methoxyethanol.
4-hydroxycoumarin	The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Lenalidomide.
9-(N-methyl-L-isoleucine)-cyclosporin A	The risk or severity of adverse effects can be increased when Lenalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abacavir	Lenalidomide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abatacept	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Lenalidomide.
Abemaciclib	The serum concentration of Lenalidomide can be increased when it is combined with Abemaciclib.
Abetimus	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abetimus.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

When given with a fatty meal, the extent of absorption is reduced.

References

Synthesis Reference

Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, "PREPARATION OF LENALIDOMIDE." U.S. Patent US20110021567, issued January 27, 2011.

US20110021567

General References

List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420]
Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772]
Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099]

External Links

Human Metabolome Database: HMDB0014623
KEGG Drug: D04687
PubChem Compound: 216326
PubChem Substance: 46505725
ChemSpider: 187515
BindingDB: 65454
ChEBI: 63791
ChEMBL: CHEMBL848
Therapeutic Targets Database: DAP001255
PharmGKB: PA162363968
Wikipedia: Lenalidomide

ATC Codes

L04AX04 — Lenalidomide

AHFS Codes

10:00.00 — Antineoplastic Agents

FDA label

Download (400 KB)

MSDS

Download (225 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Basic Science	Plasma Cell Myeloma	1
0	Terminated	Treatment	Adult T-cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease / Leukemia, Adult T-Cell / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphoma Unspecified / T/Null Cell Systemic Type	1
0	Terminated	Treatment	Multiple Myeloma (MM)	1
0	Unknown Status	Treatment	Myelodysplasia	1
1	Active Not Recruiting	Treatment	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia	1
1	Active Not Recruiting	Treatment	Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / CD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma	1
1	Active Not Recruiting	Treatment	Ann Arbor Stage III Small Lymphocytic Lymphoma / Ann Arbor Stage IV Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma	1
1	Active Not Recruiting	Treatment	B-Cell Prolymphocytic Leukemia / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma	1
1	Active Not Recruiting	Treatment	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Active Not Recruiting	Treatment	Follicular Lymphoma (FL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma	1
1	Active Not Recruiting	Treatment	Hodgkins Disease (HD)	1
1	Active Not Recruiting	Treatment	Intraocular Lymphoma / Recurrent/Refractory CNS	1
1	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Active Not Recruiting	Treatment	Leukemias	2
1	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	8
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
1	Active Not Recruiting	Treatment	Multiple Myeloma in Relapse	1
1	Active Not Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1	Active Not Recruiting	Treatment	Recurrent Colon Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Rectal Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Cancer AJCC v6 and v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Rectal Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Cancer AJCC v6 and v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Rectal Cancer / Stage IVB Rectal Cancer AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Cancer AJCC v6 and v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary	1
1	Active Not Recruiting	Treatment	Recurrent Neuroblastoma / Refractory Neuroblastoma / Stage 4 Neuroblastoma	1
1	Active Not Recruiting	Treatment	Refractory/Relapsed Indolent Non-Hodgkin Lymphoma	1
1	Completed	Not Available	Healthy Volunteers	2
1	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML)	1
1	Completed	Treatment	Acute Myelogenous Leukaemia (AML)	1
1	Completed	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies	1
1	Completed	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Alkylating Agent-Related Acute Myeloid Leukemia / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Post Transplant Lymphoproliferative Disorder / Primary Cutaneous B-Cell Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Richter's Syndrome / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Completed	Treatment	Adult T-cell lymphomas/leukaemias / Peripheral T-Cell Lymphoma (PTCL)	1
1	Completed	Treatment	Advanced Cancer, Various, NOS	1
1	Completed	Treatment	Advanced Cancers	2
1	Completed	Treatment	Anaplastic Astrocytoma (AA) / Diffuse Intrinsic Pontine Glioma (DIPG) / High Grade Glioma (HGG)	1
1	Completed	Treatment	Anemias / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia (CLL) - Refractory / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Thrombocytopenias	1
1	Completed	Treatment	B Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
1	Completed	Treatment	Bone Marrow Diseases / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myeldysplastic Syndrome (MDS) / Neutropenias	1
1	Completed	Treatment	Brain and Central Nervous System Tumors	1
1	Completed	Treatment	Cancer of the Urethra / Ureteral Cancer / Urethral Cancer / Urethral Neoplasms	1
1	Completed	Treatment	Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma	1
1	Completed	Treatment	Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, B-Cell, Chronic	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Healthy, Male	1
1	Completed	Treatment	Leukemia Lymphocytic Chronic B-Cell	1
1	Completed	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell	1
1	Completed	Treatment	Lymphoma, Hodgkins	1
1	Completed	Treatment	Malignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Malignant Melanoma	1
1	Completed	Treatment	Melanoma	1
1	Completed	Treatment	Multiple Myeloma (MM)	14
1	Completed	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
1	Completed	Treatment	Myelodysplasia	1
1	Completed	Treatment	Myelodysplastic Syndrome	1
1	Completed	Treatment	Myelodysplastic Syndromes	1
1	Completed	Treatment	Myelodysplastic Syndromes (MDS)	1
1	Completed	Treatment	Myelodysplastic Syndromes / Myeloid Leukemias	1
1	Completed	Treatment	Neoplasms	1
1	Completed	Treatment	Plasma Cell Myeloma	3
1	Completed	Treatment	Prostate Cancer	1
1	Completed	Treatment	Recurrent Follicular Lymphoma	1
1	Completed	Treatment	Refractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Completed	Treatment	Relapsed Multiple Myeloma	1
1	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
1	Completed	Treatment	Relapsed/Refractory B-cell Lymphoma	1
1	Completed	Treatment	Relapsed/Refractory Mantle Cell Lymphoma	1
1	Completed	Treatment	Smoldering Multiple Myeloma (SMM)	1
1	Completed	Treatment	Tumors, Solid	1
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	2
1	Not Yet Recruiting	Treatment	Lymphoma, Hodgkins / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral	1
1	Not Yet Recruiting	Treatment	Multiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma	1
1	Recruiting	Other	Demyelinating Sensorimotor Neuropathy	1
1	Recruiting	Prevention	Smoldering Multiple Myeloma (SMM)	1
1	Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemia Recurrent / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute, recurrent Myeloid Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / ISS Stage II Plasma Cell Myeloma / ISS Stage III Plasma Cell Myeloma / Leukemias / Myelodysplastic Syndrome / Recurrent Hodgkin Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Acute Lymphoblastic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Therapy-Related Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Autoimmune Pancreatitis / IgG4-related Disease / IgG4-related Sclerosing Cholangitis / Immunoglobulin G Subclass 4 Related Disease / Retroperitoneal Fibrosis	1
1	Recruiting	Treatment	B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / CD19 Positive / Mediastinal Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mediastinal Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Marginal Zone Lymphoma / Refractory Mediastinal Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma	1
1	Recruiting	Treatment	Burkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)	1
1	Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Richter's Syndrome	1
1	Recruiting	Treatment	HLA-A*0201 Positive Cells Present / NY-ESO-1 Positive Tumor Cells Present / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Recruiting	Treatment	Haematological Malignancies / Plasma Cell Myeloma	1
1	Recruiting	Treatment	Hypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	2
1	Recruiting	Treatment	Multiple Myeloma (MM)	1
1	Recruiting	Treatment	Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Refractory High Risk Myelodysplastic Syndrome / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Neuroblastomas	1
1	Recruiting	Treatment	Partial Response of Multiple Myeloma or Plasma Cell Leukemia / Plasma Cell Myeloma	1
1	Recruiting	Treatment	Primary Central Nervous System Lymphoma (PCNSL) / Secondary Central Nervous System Lymphoma (SCNSL)	1
1	Recruiting	Treatment	Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma	1
1	Recruiting	Treatment	Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	1
1	Recruiting	Treatment	Tumors, Solid	1
1	Suspended	Treatment	B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Follicular Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma	1
1	Suspended	Treatment	Tumors, Central Nervous System	1
1	Terminated	Treatment	Acute Myelocytic Leukemia / Acute Myelogenous Leukaemia (AML) / Acute Non-Lymphocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML)	1
1	Terminated	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes	1
1	Terminated	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia	1
1	Terminated	Treatment	Adult Grade III Lymphomatoid Granulomatosis / Adult Non-Hodgkin's Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Advanced Cancers	1
1	Terminated	Treatment	B-Cell Chronic Lymphocytic Leukemia	1
1	Terminated	Treatment	Cancer of the Ovary / Fallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
1	Terminated	Treatment	Hepatocellular,Carcinoma	1
1	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Terminated	Treatment	Leukemia, Acute	1
1	Terminated	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	2
1	Terminated	Treatment	Malignant Gliomas	1
1	Terminated	Treatment	Malignant Lymphomas / Multiple Myeloma (MM)	1
1	Terminated	Treatment	Malignant Neoplasm of Colon / Rectal Carcinoma	1
1	Terminated	Treatment	Multiple Myeloma (MM)	1
1	Terminated	Treatment	Plasma Cell Myeloma	1
1	Terminated	Treatment	Prostate Cancer	1
1	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Unknown Status	Treatment	Advanced Solid Tumors	1
1	Withdrawn	Treatment	CD30-Positive Neoplastic Cells Present / Folliculotropic Mycosis Fungoides / Recurrent Mycosis Fungoides / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory, advanced Mycosis fungoides / Refractory, primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Sezary Syndrome	1
1	Withdrawn	Treatment	Leukemia, Plasma Cell	1
1	Withdrawn	Treatment	Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Multiple Myeloma (MM)	1
1, 2	Active Not Recruiting	Treatment	AIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Advanced Malignancies / Cancer, Advanced / Metastatic Cancers / Tumors, Solid	1
1, 2	Active Not Recruiting	Treatment	Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Chronic Myelomonocytic Leukemia	1
1, 2	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma	1
1, 2	Active Not Recruiting	Treatment	Follicular Lymphoma (FL)	1
1, 2	Active Not Recruiting	Treatment	Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) / Follicular Lymphoma Patients (Phase IB)	1
1, 2	Active Not Recruiting	Treatment	Grade 3a Follicular Lymphoma / Malignant Lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Follicular Lymphoma / Refractory Small Lymphocytic Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Indolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma	1
1, 2	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1, 2	Active Not Recruiting	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas	1
1, 2	Active Not Recruiting	Treatment	Lymphoma, B-Cell	1
1, 2	Active Not Recruiting	Treatment	Malignant Lymphomas	2
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	9
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Active Not Recruiting	Treatment	Non-Hodgkin's Lymphoma, Relapsed / Relapsed Hodgkin Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Recurrent Adult Hodgkin's Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Recurrent Thyroid Gland Carcinoma / Stage I Thyroid Gland Follicular Carcinoma / Stage I Thyroid Gland Follicular Carcinoma AJCC v7 / Stage I Thyroid Gland Papillary Carcinoma / Stage I Thyroid Gland Papillary Carcinoma AJCC v7 / Stage II Thyroid Gland Follicular Carcinoma / Stage II Thyroid Gland Follicular Carcinoma AJCC v7 / Stage II Thyroid Gland Papillary Carcinoma / Stage II Thyroid Gland Papillary Carcinoma AJCC v7 / Stage III Thyroid Gland Follicular Carcinoma / Stage III Thyroid Gland Follicular Carcinoma AJCC v7 / Stage III Thyroid Gland Papillary Carcinoma / Stage III Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IV Thyroid Gland Follicular Carcinoma / Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IV Thyroid Gland Papillary Carcinoma / Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVC Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7	1
1, 2	Active Not Recruiting	Treatment	Refractory Diffuse Large B Cell Lymphoma / Relapsed, Diffuse Large B-cell Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Refractory Multiple Myeloma	2
1, 2	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1, 2	Active Not Recruiting	Treatment	Relapsed or Refractory / Relapsed or Refractory B- / T-Cell Lymphomas	1
1, 2	Active Not Recruiting	Treatment	Chronic, recurrent Lymphocytic Leukemia	1
1, 2	Completed	Not Available	Cancer of the Ovary	1
1, 2	Completed	Treatment	Adult Acute Myeloblastic Leukemia / Leukemia Acute Myeloid Leukemia (AML)	1
1, 2	Completed	Treatment	Amyloidosis	1
1, 2	Completed	Treatment	Cancer Cachexia Syndrome	1
1, 2	Completed	Treatment	Carcinoma, Pancreatic	1
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL)	5
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)	1
1, 2	Completed	Treatment	Diffuse Large B Cell Lymphoma Relapsed / Refractory Diffuse Large B Cell Lymphoma	1
1, 2	Completed	Treatment	Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / Marginal Zone Lymphoma	1
1, 2	Completed	Treatment	Kaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma	1
1, 2	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1, 2	Completed	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell	1
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes	1
1, 2	Completed	Treatment	Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)	1
1, 2	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1, 2	Completed	Treatment	Malignancies, Hematologic / Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Malignant Lymphomas	2
1, 2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	2
1, 2	Completed	Treatment	Multiple Myeloma (MM)	10
1, 2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Completed	Treatment	Plasma Cell Myeloma	1
1, 2	Completed	Treatment	Plasma Cell Myeloma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1, 2	Completed	Treatment	Plasma Cell Myeloma / Transplantation, Stem Cell	1
1, 2	Completed	Treatment	Prostate Cancer	2
1, 2	Completed	Treatment	Recurrent Ovarian Cancer	1
1, 2	Completed	Treatment	Refractory Multiple Myeloma / Relapses	1
1, 2	Completed	Treatment	Waldenström's Macroglobulinemia (WM)	1
1, 2	Enrolling by Invitation	Treatment	Multiple Myeloma (MM)	1
1, 2	Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia	1
1, 2	Recruiting	Treatment	Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)	1
1, 2	Recruiting	Treatment	CD20 Positive / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Recurrent Transformed Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Transformed Non-Hodgkin Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma	1
1, 2	Recruiting	Treatment	Follicular Lymphoma (FL) / Non Hodgkin Lymphoma (NHL)	1
1, 2	Recruiting	Treatment	Folliculotropic Mycosis Fungoides / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified / Refractory, advanced Mycosis fungoides / Sezary Syndrome	1
1, 2	Recruiting	Treatment	Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma	1
1, 2	Recruiting	Treatment	Lymphoma, B Cell / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Lymphoma, B-Cell / Primary Effusion Lymphomas	1
1, 2	Recruiting	Treatment	Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Multiple Myeloma (MM)	2
1, 2	Recruiting	Treatment	Recurrent Central Nervous System Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Central Nervous System Lymphoma / Refractory Diffuse Large B Cell Lymphoma	1
1, 2	Suspended	Treatment	Recurrent Plasma Cell Myeloma	1
1, 2	Suspended	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1, 2	Terminated	Other	Chronic Lymphocytic Leukaemia (CLL)	1
1, 2	Terminated	Treatment	Adenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer	1
1, 2	Terminated	Treatment	Aggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant	1
1, 2	Terminated	Treatment	Cancer of the Ovary	1
1, 2	Terminated	Treatment	Cancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer	1
1, 2	Terminated	Treatment	Low to Intermediate-1 MDS / Myelodysplastic Syndrome / Non-deletion 5q / Smith-Magenis Syndrome	1
1, 2	Terminated	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC) / Relapsed or Refractory Solid Tumors	1
1, 2	Terminated	Treatment	Lymphoma, Hodgkins / Mature T-cell Lymphoma / Multiple Myeloma (MM)	1
1, 2	Terminated	Treatment	Malignant Lymphomas	2
1, 2	Terminated	Treatment	Malignant Neoplasm of Pancreas	1
1, 2	Terminated	Treatment	Multiple Myeloma (MM)	3
1, 2	Terminated	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
1, 2	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Terminated	Treatment	Peripheral T-Cell Non-Hodgkin's Lymphoma	1
1, 2	Terminated	Treatment	Relapsed Or Refractory Multiple Myeloma	1
1, 2	Terminated	Treatment	Renal Cell Adenocarcinoma	1
1, 2	Terminated	Treatment	Urinary Bladder Neoplasms	1
1, 2	Unknown Status	Treatment	Amyloidosis	1
1, 2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1, 2	Unknown Status	Treatment	Multiple Myeloma (MM)	4
1, 2	Unknown Status	Treatment	Tumors, Solid	1
1, 2	Withdrawn	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1, 2	Withdrawn	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
1, 2	Withdrawn	Treatment	Follicular Lymphoma (FL) / Malignant Lymphomas	1
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM)	2
1, 2	Withdrawn	Treatment	Myeloma Multiple	1
1, 2	Withdrawn	Treatment	Plasma Cell Leukemia in Remission / Plasma Cell Myeloma	1
2	Active Not Recruiting	Supportive Care	Multiple Myeloma (MM)	1
2	Active Not Recruiting	Treatment	Adult Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia-1 / Chronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts	1
2	Active Not Recruiting	Treatment	Adult T-cell lymphomas/leukaemias	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage I Small Lymphocytic Lymphoma / Ann Arbor Stage II Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene / Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage II Grade 1 Follicular Lymphoma / Ann Arbor Stage II Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Bulky Disease / Fevers / Follicular Lymphoma (FL) / Grade 3a Follicular Lymphoma / Night Sweats / Obese experiencing rapid weight loss / Splenomegaly / Tiredness	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma / Ann Arbor Stage III Marginal Zone Lymphoma / Ann Arbor Stage III Small Lymphocytic Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma / Ann Arbor Stage IV Marginal Zone Lymphoma / Ann Arbor Stage IV Small Lymphocytic Lymphoma / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	3
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	2
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukemia (CLL) - Refractory / Contiguous Stage II Small Lymphocytic Lymphoma / Leukemia, Prolymphocytic / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Small Lymphocytic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Leukemias / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma	1
2	Active Not Recruiting	Treatment	Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
2	Active Not Recruiting	Treatment	Diffuse Large B-Cell Lymphoma Unclassifiable / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Follicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / MALT Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Follicular Lymphoma (FL) / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Hematopoietic Cell Transplantation Recipient / Plasma Cell Myeloma	2
2	Active Not Recruiting	Treatment	Histiocytic Sarcoma (HS) / Histiocytoses Erdheim-chester Disease / Langerhans Cell Histiocytosis (LCH)	1
2	Active Not Recruiting	Treatment	Lenalidomide / Malignant Lymphomas / Relapses / Rituximab	1
2	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	Leukemia, Plasma Cell / Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Active Not Recruiting	Treatment	Malignant Lymphomas	4
2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	2
2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL) / Untreated	1
2	Active Not Recruiting	Treatment	Monoclonal B-Cell Lymphocytosis / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma	1
2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	22
2	Active Not Recruiting	Treatment	Myelodysplastic Syndrome	2
2	Active Not Recruiting	Treatment	Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	Myelodysplastic Syndrome / Smith-Magenis Syndrome	1
2	Active Not Recruiting	Treatment	Neoplasms, Thyroid	1
2	Active Not Recruiting	Treatment	Neurofibromatosis Type 1 / Recurrent Childhood Pilocytic Astrocytoma / Recurrent Childhood Visual Pathway Glioma	1
2	Active Not Recruiting	Treatment	Newly Diagnosed Multiple Myeloma	1
2	Active Not Recruiting	Treatment	Non Hodgkin Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Smith-Magenis Syndrome	1
2	Active Not Recruiting	Treatment	Smoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma	1
2	Active Not Recruiting	Treatment	Smoldering Multiple Myeloma (SMM) / Smoldering Myeloma	1
2	Active Not Recruiting	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Active Not Recruiting	Treatment	T-Cell Lymphomas	1
2	Completed	Not Available	Impaired Renal Function / Multiple Myeloma (MM)	1
2	Completed	Not Available	Plasma Cell Dyscrasia	1
2	Completed	Treatment	Acute Myelogenous Leukaemia (AML) / Leukemia Acute Myeloid Leukemia (AML)	1
2	Completed	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Completed	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Untreated Adult Acute Myeloid Leukemia	1
2	Completed	Treatment	Adult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma	1
2	Completed	Treatment	Adult T Cell Leukemia/Lymphoma	1
2	Completed	Treatment	Advanced Myeloma / Plasma Cell Myeloma	1
2	Completed	Treatment	Agnogenic Myeloid Metaplasia	2
2	Completed	Treatment	Amyloidosis	2
2	Completed	Treatment	Angiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
2	Completed	Treatment	Autism, Early Infantile	1
2	Completed	Treatment	Bladder Cancers	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL)	6
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Fevers / Hypogammaglobulinemia / Lymphadenopathy / Lymphocytosis / Night Sweats / Paraproteinemia / Small Lymphocytic Lymphoma (SLL) / Thrombocytopenias / Tiredness	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	2
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias / Small Lymphocytic Lymphoma (SLL)	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	3
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia	1
2	Completed	Treatment	Complex Regional Pain Syndrome (RSD)	1
2	Completed	Treatment	Crohn's Disease (CD)	1
2	Completed	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Completed	Treatment	Essential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis	1
2	Completed	Treatment	Follicular Lymphoma (FL)	1
2	Completed	Treatment	Glioblastomas / Gliosarcoma / Malignant Gliomas	1
2	Completed	Treatment	Hematologic Cancers	1
2	Completed	Treatment	Hodgkins Disease (HD)	2
2	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	4
2	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome	1
2	Completed	Treatment	Leukemia, Lymphocytic / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Leukemia, Lymphocytic / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	1
2	Completed	Treatment	Leukemias	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
2	Completed	Treatment	Liver Cancer	2
2	Completed	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Completed	Treatment	Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)	1
2	Completed	Treatment	Malignant Lymphomas	3
2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	3
2	Completed	Treatment	Melanoma	1
2	Completed	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Completed	Treatment	Multiple Myeloma (MM)	32
2	Completed	Treatment	Multiple Myeloma (MM) / Renal Failure	1
2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	5
2	Completed	Treatment	Myelodysplastic Syndrome	2
2	Completed	Treatment	Myelodysplastic Syndromes	7
2	Completed	Treatment	Myeloid Leukemias	1
2	Completed	Treatment	Myeloproliferative Disorders	1
2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	3
2	Completed	Treatment	POEMS Syndrome	2
2	Completed	Treatment	Pancreatic Cancer Metastatic	1
2	Completed	Treatment	Plasma Cell Myeloma	1
2	Completed	Treatment	Primary Plasma Cell Leukemia	1
2	Completed	Treatment	Primary Systemic Amyloidosis	1
2	Completed	Treatment	Prostate Cancer	2
2	Completed	Treatment	Recurrent Mantle Cell Lymphoma	1
2	Completed	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Completed	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Completed	Treatment	Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)	1
2	Completed	Treatment	Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)	1
2	Completed	Treatment	Renal Cancers	2
2	Completed	Treatment	Squamous Cell Carcinoma (SCC)	1
2	Completed	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Completed	Treatment	T-Cell Lymphomas	1
2	Completed	Treatment	Light chain amyloidosis	1
2	Not Yet Recruiting	Treatment	Amyloidosis / Multiple Myeloma (MM)	1
2	Not Yet Recruiting	Treatment	Follicular Lymphoma (FL)	1
2	Not Yet Recruiting	Treatment	High Risk / Newly Diagnosed / Plasma Cell Myeloma	1
2	Not Yet Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	2
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	4
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM) / Smoldering Multiple Myeloma (SMM)	1
2	Not Yet Recruiting	Treatment	Newly Diagnosed Multiple Myeloma	1
2	Not Yet Recruiting	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
2	Not Yet Recruiting	Treatment	Primary Intraocular Lymphoma	1
2	Not Yet Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Adult Myelodysplastic Syndrome / Anemias / Chronic Myelomonocytic Leukemia	1
2	Recruiting	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome	1
2	Recruiting	Treatment	B-cell Non-Hodgkin's Lymphomas / Blood And Marrow Transplantation / Hematopoietic and Lymphoid Cell Neoplasm / Leukemias / Malignant Lymphomas / Plasma Cell Myeloma / T-Cell Non-Hodgkin Lymphoma	1
2	Recruiting	Treatment	B-cell Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Indolent Adult Non-Hodgkin Lymphoma	1
2	Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
2	Recruiting	Treatment	Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2	Recruiting	Treatment	Leukemia, Lymphocytic / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)	1
2	Recruiting	Treatment	Leukemias	1
2	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Recruiting	Treatment	Malignant Lymphomas / Neurologic toxicity / Therapy-Related Toxicity	1
2	Recruiting	Treatment	Malignant Lymphomas / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma	1
2	Recruiting	Treatment	Minimal Residual Disease / Plasma Cell Myeloma	1
2	Recruiting	Treatment	Mucosa Associated Lymphoid Tissue (MALT) Lymphoma	1
2	Recruiting	Treatment	Multiple Myeloma (MM)	17
2	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	POEMS Syndrome	1
2	Recruiting	Treatment	Plasmacytoma / POEMS Syndrome	1
2	Recruiting	Treatment	Plasma Cell Myeloma	3
2	Recruiting	Treatment	Plasma Cell Myeloma / Residual Disease	1
2	Recruiting	Treatment	Plasma Cell Myeloma / Transplant-Related Carcinoma	1
2	Recruiting	Treatment	Primary Cutaneous Anaplastic Large Cell Lymphoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory, primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma	1
2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Recruiting	Treatment	Recurrent Primary Amyloidosis	1
2	Recruiting	Treatment	Refractory Diffuse Large B Cell Lymphoma	1
2	Recruiting	Treatment	Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma	1
2	Recruiting	Treatment	Relapsed/Refractory Mantle Cell Lymphoma	1
2	Recruiting	Treatment	Smoldering Multiple Myeloma (SMM)	2
2	Recruiting	Treatment	Smouldering Myeloma	1
2	Suspended	Treatment	Multiple Myeloma (MM)	1
2	Suspended	Treatment	Smoldering Multiple Myeloma (SMM)	1
2	Terminated	Other	Haematological disorders	1
2	Terminated	Supportive Care	Neuropathy / Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)	1
2	Terminated	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Terminated	Treatment	Cancer, Advanced / Pain NOS	1
2	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL)	4
2	Terminated	Treatment	Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	1
2	Terminated	Treatment	Colorectal Cancers	1
2	Terminated	Treatment	Complex Regional Pain Syndrome, Type I	1
2	Terminated	Treatment	Follicular Lymphoma (FL) / Marginal Zone Lymphoma	1
2	Terminated	Treatment	Graft Versus Host Disease (GVHD)	1
2	Terminated	Treatment	HIV Infection Associated Kaposi Disease	1
2	Terminated	Treatment	Intraocular Melanoma / Malignant Conjunctival Neoplasm	1
2	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndromes (MDS)	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Relapsed Adult Acute Lymphocytic Leukemia	1
2	Terminated	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Terminated	Treatment	Multiple Myeloma (MM)	7
2	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
2	Terminated	Treatment	Myelodysplastic Syndrome	1
2	Terminated	Treatment	Myelodysplastic Syndrome MDS	1
2	Terminated	Treatment	Myelodysplastic Syndromes	1
2	Terminated	Treatment	Peripheral T-Cell Lymphoma (PTCL)	1
2	Terminated	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Terminated	Treatment	Refractory Plasma Cell Myeloma	1
2	Terminated	Treatment	Smith-Magenis Syndrome	1
2	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Terminated	Treatment	T-Cell Non-Hodgkin Lymphoma	1
2	Terminated	Treatment	Waldenström's Macroglobulinemia (WM)	2
2	Unknown Status	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL) / First-Line / Front-line / Initial Therapy / Untreated	1
2	Unknown Status	Treatment	Cutaneous T Cell Lymphomas (CTCL)	1
2	Unknown Status	Treatment	Indolent Non Hodgkin Lymphoma	1
2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Unknown Status	Treatment	MALT Lymphoma	1
2	Unknown Status	Treatment	Malignant Lymphomas	1
2	Unknown Status	Treatment	Multiple Myeloma (MM)	1
2	Unknown Status	Treatment	Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Myelodysplastic Syndromes	1
2	Unknown Status	Treatment	POEMS Syndrome	1
2	Unknown Status	Treatment	Refractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Withdrawn	Treatment	Chronic Lymphocytic Leukaemia (CLL)	2
2	Withdrawn	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia	1
2	Withdrawn	Treatment	EBV Related Non-Hodgkin's Lymphoma / Primary Central Nervous System Lymphoma (PCNSL) / Primary Testicular Lymphoma	1
2	Withdrawn	Treatment	Hematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)	1
2	Withdrawn	Treatment	Leukemias / Malignant Lymphomas	1
2	Withdrawn	Treatment	Malignant Gliomas	1
2	Withdrawn	Treatment	Multiple Myeloma (MM)	4
2	Withdrawn	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2	Withdrawn	Treatment	Relapse/Refractory Multiple Myeloma	1
2, 3	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2, 3	Completed	Treatment	Multiple Myeloma (MM)	1
2, 3	Completed	Treatment	Radicular syndrome	1
2, 3	Terminated	Treatment	Multiple Myeloma (MM)	1
3	Active Not Recruiting	Basic Science	Newly Diagnosed, Previously Untreated Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Anemias / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes	1
3	Active Not Recruiting	Treatment	B-Cell Chronic Lymphocytic Leukemia	1
3	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Follicular Lymphoma (FL)	2
3	Active Not Recruiting	Treatment	Light Chain Deposition Disease / Smoldering Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	Lymphoma (Myeloma) / Malignant Lymphomas / Multiple Myeloma (MM)	1
3	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
3	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas	1
3	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
3	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	13
3	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Newly Diagnosed Patients	1
3	Active Not Recruiting	Treatment	Myelodysplastic Syndrome	1
3	Active Not Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
3	Active Not Recruiting	Treatment	Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Previously Untreated Symptomatic Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Solitary Osseous Plasmacytoma	1
3	Completed	Diagnostic	Multiple Myeloma (MM)	1
3	Completed	Prevention	Melanoma / Neoplasms Metastasis	1
3	Completed	Treatment	Anemias	1
3	Completed	Treatment	B-Cell Chronic Lymphocytic Leukemia / B-Cell Chronic Lymphocytic Leukemia (B-CLL)	1
3	Completed	Treatment	Multiple Myeloma (MM)	13
3	Completed	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
3	Completed	Treatment	Myelodysplastic Syndromes	1
3	Completed	Treatment	Newly Diagnosed Multiple Myeloma	1
3	Completed	Treatment	Plasma Cell Myeloma	2
3	Completed	Treatment	Prostate Cancer	1
3	Completed	Treatment	Relapsed Multiple Myeloma	1
3	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
3	Not Yet Recruiting	Treatment	Autologous Stem Cell Transplant Recipient / Minimal Residual Disease / Plasma Cell Myeloma	1
3	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	1
3	Recruiting	Treatment	Follicular Lymphoma (FL)	1
3	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
3	Recruiting	Treatment	Multiple Myeloma (MM)	10
3	Recruiting	Treatment	Multiple Myeloma in Relapse / Refractory Multiple Myeloma	1
3	Recruiting	Treatment	Newly Diagnosed Multiple Myeloma	1
3	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
3	Recruiting	Treatment	Plasma Cell Myeloma	1
3	Recruiting	Treatment	Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Recruiting	Treatment	Plasmacytoma	1
3	Recruiting	Treatment	Relapsed Or Refractory Multiple Myeloma	1
3	Recruiting	Treatment	Relapsed or Refractory Systemic Light Chain Amyloidosis	1
3	Recruiting	Treatment	Smoldering Plasma Cell Myeloma	1
3	Terminated	Treatment	Malignant Lymphomas	1
3	Terminated	Treatment	Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)	1
3	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Withdrawn	Treatment	Blood Protein Disorders / Hematologic Diseases / Multiple Myeloma (MM) / Neoplasms / Paraproteinemias / Plasma Cells / Therapeutic Uses	1
4	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
4	Completed	Treatment	Cutaneous Lupus	1
4	Completed	Treatment	Multiple Myeloma (MM)	1
4	Not Yet Recruiting	Treatment	Relapsed Refractory Multiple Myeloma	1
4	Recruiting	Treatment	Multiple Myeloma (MM)	2
4	Recruiting	Treatment	Relapsed and/or Refractory Multiple Myeloma	1
4	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
Not Available	Active Not Recruiting	Not Available	Myelodysplastic Syndrome / Myelodysplastic Syndromes (MDS)	1
Not Available	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
Not Available	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
Not Available	Completed	Not Available	Multiple Myeloma (MM)	2
Not Available	Completed	Not Available	Myelodysplastic Syndrome	1
Not Available	Completed	Treatment	Amyloidosis / Leukemias	1
Not Available	Completed	Treatment	Anemias / Dysmyelopoietic Syndromes / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Myelocytic, Acute / Leukemias / Myelodysplastic Syndromes (MDS)	1
Not Available	Completed	Treatment	Cutaneous Lupus Erythematosus (CLE)	1
Not Available	Completed	Treatment	Multiple Myeloma (MM)	1
Not Available	Not Yet Recruiting	Not Available	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
Not Available	Recruiting	Not Available	Malignant Lymphomas	1
Not Available	Recruiting	Not Available	Mantle Cell Lymphoma (MCL)	1
Not Available	Recruiting	Not Available	Multiple Myeloma (MM)	2
Not Available	Recruiting	Not Available	Relapsed and/or Refractory Multiple Myeloma	1
Not Available	Terminated	Not Available	Multiple Myeloma (MM)	1
Not Available	Terminated	Treatment	B-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia	1
Not Available	Terminated	Treatment	Plasma Cell Myeloma	1

Pharmacoeconomics

Manufacturers

Celgene corp
Celgene Corporation

Packagers

Celgene
Norwich Pharmaceuticals Inc.
Penn Pharmaceutical Services Ltd.

Dosage forms

Form	Route	Strength
Capsule	Oral	10 mg/1
Capsule	Oral	10 mg
Capsule	Oral	15 mg
Capsule	Oral	15 mg/1
Capsule	Oral	2.5 mg/1
Capsule	Oral	2.5 mg
Capsule	Oral	20 mg/1
Capsule	Oral	20 mg
Capsule	Oral	25 mg
Capsule	Oral	25 mg/1
Capsule	Oral	5 mg
Capsule	Oral	5 mg/1
Capsule	Oral	7.5 mg

Prices

Unit description	Cost	Unit
Revlimid 25 mg capsule	411.71USD	capsule
Revlimid 15 mg capsule	407.7USD	capsule
Revlimid 10 mg capsule	406.05USD	capsule
Revlimid 5 mg capsule	388.0USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
Unlock Additional Data
CA2477301	No	2009-09-01	2023-04-13
CA2342974	No	2005-08-16	2014-02-24
US6045501	No	2000-04-04	2018-08-28
US6315720	No	2001-11-13	2020-10-23
US6561976	No	2003-05-13	2018-08-28
US6561977	No	2003-05-13	2020-10-23
US6755784	No	2004-06-29	2020-10-23
US6908432	No	2005-06-21	2018-08-28
US8204763	No	2012-06-19	2018-08-28
US8315886	No	2012-11-20	2020-10-23
US8626531	No	2014-01-07	2020-10-23
US8589188	No	2013-11-19	2018-08-28
US7468363	No	2008-12-23	2023-10-07
US6281230	No	2001-08-28	2016-07-24
US8530498	No	2013-09-10	2023-05-15
US6555554	No	2003-04-29	2016-07-24
US7189740	No	2007-03-13	2023-04-11
US7968569	No	2011-06-28	2023-10-07
US8404717	No	2013-03-26	2023-04-11
US8648095	No	2014-02-11	2023-05-15
US8741929	No	2014-06-03	2028-03-08
US9101622	No	2015-08-11	2023-05-15
US9101621	No	2015-08-11	2023-05-15
US9056120	No	2015-06-16	2023-04-11
US5635517	No	1997-06-03	2019-10-04
US7119106	No	2006-10-10	2016-07-24
US7465800	No	2008-12-16	2027-04-27
US7855217	No	2010-12-21	2024-11-24
US8288415	No	2012-10-16	2016-07-24

Additional Data Available

Filed On

The date on which a patent was filed with the relevant government.

Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.	Not Available
logP	-0.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	2.33 mg/mL	ALOGPS
logP	-0.43	ALOGPS
logP	-0.71	ChemAxon
logS	-2	ALOGPS
pKa (Strongest Acidic)	11.61	ChemAxon
pKa (Strongest Basic)	2.31	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	92.5 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	68.3 m³·mol^-1	ChemAxon
Polarizability	25.55 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9958
Blood Brain Barrier	+	0.9372
Caco-2 permeable	-	0.5981
P-glycoprotein substrate	Substrate	0.6845
P-glycoprotein inhibitor I	Inhibitor	0.6012
P-glycoprotein inhibitor II	Non-inhibitor	0.8927
Renal organic cation transporter	Non-inhibitor	0.726
CYP450 2C9 substrate	Non-substrate	0.8861
CYP450 2D6 substrate	Non-substrate	0.7878
CYP450 3A4 substrate	Substrate	0.5855
CYP450 1A2 substrate	Non-inhibitor	0.8746
CYP450 2C9 inhibitor	Non-inhibitor	0.8405
CYP450 2D6 inhibitor	Non-inhibitor	0.8806
CYP450 2C19 inhibitor	Non-inhibitor	0.78
CYP450 3A4 inhibitor	Non-inhibitor	0.7469
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.843
Ames test	Non AMES toxic	0.8268
Carcinogenicity	Non-carcinogens	0.9068
Biodegradation	Not ready biodegradable	0.9967
Rat acute toxicity	2.5145 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9803
hERG inhibition (predictor II)	Non-inhibitor	0.5098

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0002-1920000000-c10c48acd9b8123e3505

Taxonomy

Description: This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Isoindoles and derivatives
Sub Class: Isoindolines
Direct Parent: Isoindolones
Alternative Parents: Alpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / Benzenoids / Tertiary carboxylic acid amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds / Primary amines
show 4 more
Substituents: Alpha-amino acid or derivatives / Isoindolone / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Piperidine / Benzenoid / Carboxylic acid imide / Dicarboximide
show 18 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: dicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:63791)

Targets

Details1. Protein cereblon

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Metal ion binding
Specific Function: Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Norma...
Gene Name: CRBN
Uniprot ID: Q96SW2
Uniprot Name: Protein cereblon
Molecular Weight: 50545.375 Da

References

Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948]

Details2. Tumor necrosis factor ligand superfamily member 11

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Tumor necrosis factor receptor superfamily binding
Specific Function: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be...
Gene Name: TNFSF11
Uniprot ID: O14788
Uniprot Name: Tumor necrosis factor ligand superfamily member 11
Molecular Weight: 35477.81 Da

References

Akobeng AK, Stokkers PC: Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. doi: 10.1002/14651858.CD007351.pub2. [PubMed:19370685]
Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. Epub 2007 Jan 30. [PubMed:17369076]

Details3. Cadherin-5

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist

General Function: Receptor binding
Specific Function: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of hete...
Gene Name: CDH5
Uniprot ID: P33151
Uniprot Name: Cadherin-5
Molecular Weight: 87527.715 Da

References

Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. [PubMed:18805433]

Details4. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Negative modulator

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name: PTGS2
Uniprot ID: P35354
Uniprot Name: Prostaglandin G/H synthase 2
Molecular Weight: 68995.625 Da

References

Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423]
Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81. [PubMed:12720152]

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

Drug created on June 13, 2005 07:24 / Updated on June 16, 2019 06:45

Lenalidomide

Identification

Structure for Lenalidomide (DB00480)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

References

Transporters